DDInter31 DDInter927
The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Adenosine {u} (Compound) resembles {v} (Compound) Azacitidine
Adenosine {u} (Compound) resembles {v} (Compound) Nelarabine
Adenosine {u} (Compound) binds {v} (Gene) ADORA2B
Adenosine {u} (Compound) is included by {v} (Pharmacologic Class) Adenosine Receptor Agonists
Adenosine {u} (Compound) downregulates {v} (Gene) KIF14
Adenosine {u} (Compound) causes {v} (Side Effect) Atrioventricular block
Adenosine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cilostazol
Adenosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Caffeine
Adenosine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Adenosine (Compound) resembles Azacitidine (Compound)
Adenosine (Compound) resembles Nelarabine (Compound)
Adenosine (Compound) binds ADORA2B (Gene)
Adenosine (Compound) is included by Adenosine Receptor Agonists (Pharmacologic Class)
Adenosine (Compound) downregulates KIF14 (Gene)
Adenosine (Compound) causes Atrioventricular block (Side Effect)
Adenosine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Caffeine
Adenosine may lead to a major life threatening interaction when taken with Ribociclib